| Are there specific translational challenges in regenerative medicine? Lessons from other fields J Gardner, A Faulkner, A Mahalatchimy, A Webster Regenerative Medicine 10 (7), 885-895, 2015 | 49 | 2015 |
| The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom A Mahalatchimy, E Rial‐Sebbag, V Tournay, A Faulkner Journal of law and society 39 (1), 131-149, 2012 | 37 | 2012 |
| Reimbursement of cell-based regenerative therapy in the UK and France A Mahalatchimy Medical law review 24 (2), 234-258, 2016 | 24 | 2016 |
| Human stem cells patents—Emerging issues and challenges in Europe, United States, China, and Japan AYT Wong, A Mahalatchimy The Journal of world intellectual property 21 (5-6), 326-355, 2018 | 20 | 2018 |
| Communication of results and disclosure of incidental findings in longitudinal paediatric research V Anastasova, A Mahalatchimy, E Rial‐Sebbag, JM Anto Boque, T Keil, ... Pediatric Allergy and Immunology 24 (4), 389-394, 2013 | 20 | 2013 |
| The impact of European embryonic stem cell patent decisions on research strategies A Mahalatchimy, E Rial-Sebbag, AM Duguet, F Taboulet, ... Nature Biotechnology 33 (1), 41-43, 2015 | 14 | 2015 |
| Access to advanced therapy medicinal products in the EU: where do we stand? A Mahalatchimy European journal of health law 18 (3), 305-317, 2011 | 13 | 2011 |
| Exclusion of patentability of embryonic stem cells in Europe: another restriction by the European Patent Office A Mahalatchimy, E Rial-Sebbag, M Duguet, A Cambon-Thomsen, ... European Intellectual Property Review 37 (1), 25-28, 2015 | 9 | 2015 |
| The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics A Mahalatchimy, A Faulkner Regenerative medicine 12 (6), 611-622, 2017 | 8 | 2017 |
| Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginary A Mahalatchimy, PL Lau, P Li, ML Flear Journal of Law and the Biosciences 8 (2), lsaa080, 2021 | 7 | 2021 |
| The politics of valuation and payment for regenerative medicine products in the UK A Faulkner, A Mahalatchimy New Genetics and Society 37 (3), 227-247, 2018 | 6 | 2018 |
| Accreditation and regulations in cell therapy C Chabannon, O Caunday‐Rigot, C Faucher, I Slaper‐Cortenbach, ... ISBT Science Series 11 (S1), 271-276, 2016 | 6 | 2016 |
| Les unités de thérapie cellulaire à l’épreuve de la réglementation sur les médicaments de thérapie innovante C Chabannon, F Sabatier, E Rial-Sebbag, B Calmels, J Veran, ... médecine/sciences 30 (5), 576-583, 2014 | 5 | 2014 |
| Regulating Medicines in the European Union A Mahalatchimy | 4 | 2020 |
| EU law and policy on new health technologies E Brosset, A Mahalatchimy Research handbook on EU health law and policy, 197-221, 2017 | 4 | 2017 |
| Does the French Bioethics Law create a'moral exception'to the use of human cells for health? A legal and organizational issue A Mahalatchimy, E Rial-Sebbag, V Tournay, A Faulkner Dilemata, 17-37, 2011 | 4 | 2011 |
| Bioethics and European Union: the advanced therapy medicinal products’ case A Mahalatchimy Opinio Juris in Compratione 2, 2010 | 4 | 2010 |
| Chapitre 6. Cells’ safety in Europe: Towards an ethical safety E Rial-Sebbag*, A Mahalatchimy**, AM Duguet*** Journal International de Bioéthique 28 (2), 107-129, 2017 | 3 | 2017 |
| Le monopole pharmaceutique en Grande-Bretagne A Mahalatchimy Cahier de Droit de la Santé juridiques, historiques et prospectifs, 109-127, 2017 | 3 | 2017 |
| The European Medicines Agency: a public health European agency A Mahalatchimy, E Rial-Sebbag, N De Grove-Valdeyron, V Tournay, ... Med. & L. 31, 25, 2012 | 3 | 2012 |
Florence TabouletUniversité Toulouse 3Email verificata su univ-tlse3.fr
